$52.74
-2.38-4.32%
Últ. Act.: Nov 5, 6:30 PM
Genmab (GMAB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Genmab (GMAB) publicó su última previsión de noviembre 5, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $4.33B - $4.53B para el período.
En comparación con la previsión anterior, Genmab mantenido redujo su previsión de ingresos desde un rango anterior de $4.33B - $4.53B.
Genmab ha emitido 17 actualizaciones de orientación entre el noviembre 9, 2022 y el noviembre 5, 2026. During this period, the company raised its outlook 10 times, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.33 | $0.31 | $0.17 | $0.44 |
| Actual | $5.51 | $4.91 | $0.08 | $0.05 |
| Surprise | +1569.7% | +1483.9% | -51.2% | -88.6% |
| Revenue | ||||
| Estimate | $6.69B | $5.81B | $4.71B | $4.40B |
| Actual | $1.19B | $1.16B | $896.0M | $1.06B |
| Surprise | -82.3% | -80.1% | -81.0% | -76.0% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.27 | $0.24 | $0.45 | $0.47 |
| Revenue | ||||
| Consensus | $7.12B | — | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $5.51 | $0.33 | 1569.7 % |
| Q2 | Aug 6, 2026 | $4.91 | $0.31 | 1483.9 % |
| Q1 | May 7, 2026 | $0.08 | $0.17 | -51.2 % |
| Q4 | Feb 17, 2026 | $0.05 | $0.44 | -88.6 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $1.19B | $6.69B | -82.3 % |
| Q2 | Aug 6, 2026 | $1.16B | $5.81B | -80.1 % |
| Q1 | May 7, 2026 | $896.00M | $4.71B | -81.0 % |
| Q4 | Feb 17, 2026 | $1.06B | $4.40B | -76.0 % |